Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.25) by 12 percent. This is a 30 percent increase over losses of $(0.40) per share from the same period last year. The company reported quarterly sales of $856.000 thousand which missed the analyst consensus estimate of $1.065 million by 19.66 percent. This is a 41.13 percent decrease over sales of $1.454 million the same period last year.